Adicet Bio, Inc.(ACET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACET Adicet Bio, Inc.

Market Closed 03-21 16:00:00 EDT

0.7661

+0.0018

+0.24%

盘后0.7600

-0.0061-0.80%

19:59 EDT

High0.7900	Low0.7407	Vol186.35K
Open0.7643	D1 Closing0.7643	Amplitude6.45%
Mkt Cap63.35M	Tradable Cap47.01M	Total Shares82.69M
T/O142.64K	T/O Rate0.30%	Tradable Shares61.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ACET","market":"US","secType":"STK","nameCN":"Adicet Bio, Inc.","latestPrice":0.7661,"timestamp":1742587200000,"preClose":0.7643,"halted":0,"volume":186352,"hourTrading":{"tag":"盘后","latestPrice":0.76,"preClose":0.7661,"latestTime":"19:59 EDT","volume":977,"amount":745.9972,"timestamp":1742601572752},"delay":0,"floatShares":61366114,"shares":82685750,"eps":-1.332954,"marketStatus":"Market Closed","change":0.0018,"latestTime":"03-21 16:00:00 EDT","open":0.7643,"high":0.79,"low":0.7407,"amount":142636.336552,"amplitude":0.064503,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.332954,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742803200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1516942800000,"exchange":"NASDAQ","adjPreClose":0.7643,"preHourTrading":{"tag":"盘前","latestPrice":0.7812,"preClose":0.7643,"latestTime":"08:40 EDT","volume":59,"amount":45.6812987,"timestamp":1742560857272},"postHourTrading":{"tag":"盘后","latestPrice":0.76,"preClose":0.7661,"latestTime":"19:59 EDT","volume":977,"amount":745.9972,"timestamp":1742601572752},"volumeRatio":1.3536245574344545,"impliedVol":1.923,"impliedVolPercentile":0.952},"requestUrl":"/m/hq/s/ACET","defaultTab":"news","newsList":[{"id":"2521205319","title":"Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521205319","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521205319?lang=en_us&edition=full_marsco","pubTime":"2025-03-23 20:43","pubTimestamp":1742733837,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc.  stands against other penny stocks with the biggest upside potential.Further insights came from Chris Retzler, portfolio manager for Needham’s Small Cap Growth Fund, who shared his outlook for small-caps on CNBC’sSquawk Boxon January 17, 2025. He noted that small-cap companies are looking for policy certainty, and once the new administration’s direction becomes clearer, we could see growth accelerate. Globally, the EV sector is thriving, even as it faces some hurdles in the United States.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-acet-among-penny-124357821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","SQQQ","NVIW.SI","PSQ","QID","QLD","USAW.SI","USJW.SI","MNQmain","SLE","TSYW.SI","BK4139","ACET","BK4077",".IXIC","NQmain"],"gpt_icon":1},{"id":"2521803882","title":"Adicet Bio Price Target Maintained With a $7.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2521803882","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521803882?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 22:14","pubTimestamp":1742566440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACET/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 10:14 ET (14:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET"],"gpt_icon":0},{"id":"2517859394","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517859394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517859394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:00","pubTimestamp":1741345200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Algonquin Pwr & Utl                              4Q       .09       BMO. ·Asana Inc. Class A                              4Q      (.01)  4:05 PM. ·Auna S.A. Class A                               4Q       .15       AMC. ·Vail Resorts Inc.                                2Q      6.29   4:05 PM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVEX","BNTX","SSP","MOMO","MYPS","CVGW","BW","AEO","VTS","CINT","TBRG","KRMD","ASRT","CIEN","HLLY","BTMD","ADBE","ATLC","ARCO","KALV","LE","DRRX","BDTX","CDTX","ORCL","NKTR","FTCI","LRMR","URGN","CING","DRUG","NOA","FERG","CHRS","ZVRA","LMB","AMRN","WEST","MGTX","AURA","BBCP","LEN.B","ACET","BWMN","SFIX","AUNA","EWCZ","DKS","GECC"],"gpt_icon":1},{"id":"2517116113","title":"BRIEF-Adicet Bio Inc Files For Mixed Shelf Of Up To $250 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517116113","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517116113?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:59","pubTimestamp":1741298381,"startTime":"0","endTime":"0","summary":"BRIEF-Adicet Bio Inc Files For Mixed Shelf Of Up To $250 MillionMarch 6  - Adicet Bio Inc ACET.O:ADICET BIO INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILINGADICET BIO INC FILES FOR MIXED SHELF OF UP TO $250 MILLION- SEC FILINGFurther company coverage: ACET.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2517186491","title":"BRIEF-Adicet Bio Q4 Basic EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2517186491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517186491?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:01","pubTimestamp":1741294905,"startTime":"0","endTime":"0","summary":"BRIEF-Adicet Bio Q4 Basic EPS USD -0.32\n\n\nMar 06 (Reuters) - Adicet Bio Q4 net income USD -28.727 million.\n\nQ4 operating expenses USD 30.743 million\nQ4 operating income USD -30.743 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLXA4D5D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET"],"gpt_icon":0},{"id":"2517911392","title":"Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911392","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911392?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":"Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis  patient cohort in 1H25. Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25. Initiation of ADI-001 Phase 1 clinical trial patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected in 2Q25; anti-neutrophil cytoplasmic autoantibody  associated vasculitis  patient enrollment expected to be initiated in 2H25. Continuing to advance phase 1 trial of ADI-001 in autoimmune diseases. In November 2024, Adicet announced the dosing of the first patient in the Phase 1 trial evaluating ADI-001 in LN. Enrollment for SLE, SSc, IIM, and SPS patients is expected to commence in the second quarter of 2025, with the initiation of AAV patient enrollment anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-reports-fourth-quarter-210100654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4077","LU2065732104.USD","PRGS","SITC","BK4230","IIM","BK4139","CAR","BK4097","ACR","BK4231","ACET","BK4022","SLE","BK4110"],"gpt_icon":0},{"id":"2516468753","title":"Adicet Announces Poster Presentations Highlighting Adi-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2516468753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516468753?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:00","pubTimestamp":1741003201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUARHSWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2516389376","title":"Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2516389376","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516389376?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, March 03, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer  2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A.Details of the poster presentation are as follows:. Abstract Title: A Phase 1/2 First in Human Study of ADI-270, an Armored Allogeneic Anti-CD70 Chimeric Antigen Receptor γδ T Cell Therapy, in Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma Poster/Abstract Number: 136Presenting Author: Gregory Vosganian, M.D.Date/Time: Thursday, March 13, 2025, from 5:00 p.m. – 6:30 p.m. PT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-announces-poster-presentations-highlighting-120000270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0719512351.SGD","LU2237443549.SGD","IE0009356076.USD","IE00BZ199S13.USD","LU2272731600.USD","LU1861214812.USD","LU1803068979.SGD","LU2458330243.SGD","LU1992135472.HKD","LU1861219969.SGD","LU0314104364.USD","IE00B5949003.HKD","BK4588","LU2272731782.SGD","SITC","BK4585","LU2298322129.HKD","LU1244550577.SGD","LU0957808578.USD","LU0724618433.USD","BK4605","LU0124384867.USD","BK4512","BK4080","ADI","BK4231","LU1642822529.SGD","LU1074936037.SGD","ACET","LU2237438978.USD","LU0444971666.USD","LU1244550221.USD","LU1670711123.USD","LU0082616367.USD","LU1244550494.USD","LU1992135399.USD","BK4141","BK4515","LU1670710588.SGD","LU1670710661.SGD","LU2237443978.SGD","LU2360107325.USD","LU1670711040.USD","BK4139","LU1978683503.SGD","LU2237443622.USD","LU0109392836.USD","LU1815336760.USD","LU2237443382.USD"],"gpt_icon":0},{"id":"2514880016","title":"Adicet Bio shares rise on FDA Fast Track Designation for ADI-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2514880016","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514880016?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:36","pubTimestamp":1740663388,"startTime":"0","endTime":"0","summary":"Investing.com --Adicet Bio shares jumped 6.4% premarket after the company announced that the U.S. Food and Drug Administration  granted Fast Track Designation to its investigational therapy ADI-001 for the treatment of systemic sclerosis .ADI-001 is a CAR T cell therapy that targets CD20 to treat autoimmune diseases.Fast Track Designation is intended to accelerate the development and regulatory review of drugs aimed at treating serious conditions with unmet medical needs.The designation provides Adicet Bio with several potential advantages, including more frequent FDA interactions, eligibility for priority review, and the possibility of accelerated approval if clinical data supports it.This milestone strengthens Adicet Bio’s position in the cell therapy space, particularly in autoimmune diseases and cancer, where the company is focused on developing novel gamma delta T cell-based treatments.The stock’s premarket jump reflects investor optimism about the regulatory progress of ADI-001 a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-shares-rise-fda-133628680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237957902.USD","IE00B3S45H60.SGD","LU0353189680.USD","IE0004086264.USD","IE000ITXATA3.USD","LU1043141396.HKD","BK4504","LU0683600562.USD","LU0187121727.USD","LU2236285917.USD","IE00BFSS7M15.SGD","FAST","LU1366333091.USD","LU2237443382.USD","LU1992135472.HKD","LU1670627923.USD","LU2491050154.USD","BK4532","LU1301847155.USD","LU0302445910.USD","LU1116320737.USD","LU0128525929.USD","LU1988902786.USD","LU0310800379.SGD","LU1582986359.USD","LU2362540622.SGD","ACET","LU2108987350.USD","LU0072461881.USD","LU0868494617.USD","LU2413666426.HKD","LU2361044865.SGD","LU0095938881.EUR","LU0061474960.USD","LU0029864427.USD","BK4581","LU2264538146.SGD","ADI","LU0127658192.USD","LU2023250504.SGD","LU2247934214.USD","LU2237443549.SGD","LU2111349929.HKD","LU0820561818.USD","IE00B19Z9505.USD","LU1084165304.USD","LU1221951046.USD","LU2458330169.SGD","LU1267930813.SGD"],"gpt_icon":1},{"id":"2514032138","title":"Adicet Bio Receives FDA Fast Track Designation for Adi-001 for the Treatment of Systemic Sclerosis (Ssc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514032138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514032138?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 20:00","pubTimestamp":1740657612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2514806912","title":"Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806912","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806912?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, February 27, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration  has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with systemic sclerosis .Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.This press release contains \"forward-looking statements\" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"would\" and similar expressions are intended to identify forward-looking statements, althoug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-receives-fda-fast-120000634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FAST","LU1992135472.HKD","LU1670711040.USD","LU1244550494.USD","LU2237443382.USD","LU0719512351.SGD","LU2237443622.USD","LU2298322129.HKD","LU2237438978.USD","LU0724618433.USD","SLE","LU0444971666.USD","LU1642822529.SGD","LU1670710588.SGD","LU0082616367.USD","BK4230","IE00BD6J9T35.USD","LU1861219969.SGD","LU0889565833.HKD","LU2458330243.SGD","LU1670710661.SGD","ADI","LU2237443978.SGD","LU2272731782.SGD","BK4077","LU2237443549.SGD","BK4512","BK4141","LU1074936037.SGD","LU1978683503.SGD","CAR","IE00BZ199S13.USD","LU2272731600.USD","BK4515","LU1244550221.USD","LU1244550577.SGD","LU1992135399.USD","LU1803068979.SGD","LU0314104364.USD","LU0109392836.USD","LU1861214812.USD","LU2458330169.SGD","BK4561","IE00B5949003.HKD","LU0124384867.USD","LU1815336760.USD","BK4139","BK4605","ACET","IE0009356076.USD"],"gpt_icon":0},{"id":"2509872280","title":"H.C. Wainwright Sticks to Its Hold Rating for Adicet Bio (ACET)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509872280","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509872280?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 22:55","pubTimestamp":1738767314,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Edward White reiterated a Hold rating on Adicet Bio (ACET – Research Report) today. The company’s shares opened today at $1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-adicet-bio-acet-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-adicet-bio-acet-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACET"],"gpt_icon":0},{"id":"2509407348","title":"Adicet Bio Receives FDA Fast Track Designation for Adi-001 for the Treatment of Refractory Systemic Lupus Erythematosus (Sle) With Extrarenal Involvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407348?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 20:10","pubTimestamp":1738757414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW197:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2509407237","title":"Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407237","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407237?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 20:10","pubTimestamp":1738757400,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, February 05, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration  has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus  with extrarenal involvement.Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.This press release contains \"forward-looking statements\" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"would\" and similar expressions are intende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-receives-fda-fast-121000035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443622.USD","BK4512","LU2237443978.SGD","ADI","LU1815336760.USD","LU0314104364.USD","LU2272731782.SGD","LU0082616367.USD","IE0009356076.USD","BK4515","IE00B5949003.HKD","LU0109392836.USD","LU0724618433.USD","LU1642822529.SGD","LU1244550577.SGD","LU2237443382.USD","LU1670710661.SGD","IE00BZ199S13.USD","LU0719512351.SGD","BK4139","LU0889565833.HKD","LU1670711040.USD","LU1861219969.SGD","LU2298322129.HKD","LU1244550221.USD","LU1992135472.HKD","LU0444971666.USD","LU2272731600.USD","BK4588","BK4141","LU2458330243.SGD","LU2237443549.SGD","LU1670710588.SGD","BK4585","LU1074936037.SGD","BK4077","LU0124384867.USD","LU1992135399.USD","BK4230","SLE","BK4605","LU2237438978.USD","ACET","FAST","CAR","LU1670711123.USD","IE00BD6J9T35.USD","LU1978683503.SGD","LU1861214812.USD","LU2458330169.SGD"],"gpt_icon":0},{"id":"2508146915","title":"Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508146915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508146915?lang=en_us&edition=full_marsco","pubTime":"2025-02-01 07:06","pubTimestamp":1738364760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nTUA9BNSDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2508891504","title":"Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508891504","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508891504?lang=en_us&edition=full_marsco","pubTime":"2025-02-01 07:06","pubTimestamp":1738364760,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, January 31, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on January 31, 2025.All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan , which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by a majority of Adicet’s independent directors or the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635.Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-reports-inducement-grants-230600745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","ACET","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BKPKM429.USD","LU2095319765.USD","BK4585",".IXIC","LU2210149790.SGD","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112"],"gpt_icon":0},{"id":"2507687414","title":"Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507687414","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507687414?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 20:00","pubTimestamp":1738152000,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, January 29, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being held from February 5-6, 2025 in New York.Details of the event are as follows:Date: Wednesday, February 5, 2025Time: 2:00 p.m. ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-participate-fireside-chat-120000750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","BK4011","ACET","BK4139"],"gpt_icon":0},{"id":"2502083138","title":"BRIEF-Adicet Bio Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2502083138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502083138?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 05:16","pubTimestamp":1736371016,"startTime":"0","endTime":"0","summary":"BRIEF-Adicet Bio Provides Corporate Update Jan 8 (Reuters) - Adicet Bio Inc ACET.O:ADICET BIO PROVIDES CORPORATE UPDATE AND HIGHLIGHTS EXPECTED 2025 MILESTONESADICET BIO INC - PRELIMINARY DATA FOR ADI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUAB58CWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2502083595","title":"Adicet Bio Inc - Patient Enrollment for Sle, Ssc, Iim, SPS Expected in 1Q25","url":"https://stock-news.laohu8.com/highlight/detail?id=2502083595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502083595?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 05:10","pubTimestamp":1736370600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUAB58CWM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2502083591","title":"Adicet Bio Inc - Preliminary Data for Adi-001 in Ln Expected in 1H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2502083591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502083591?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 05:10","pubTimestamp":1736370600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUAB58CWM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACET"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.restorbio.com","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.2415},{"period":"3month","weight":-0.1581},{"period":"6month","weight":-0.4993},{"period":"1year","weight":-0.6245},{"period":"ytd","weight":-0.2036}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. has collaboration with TrialSpark to investigate RTB-101 for COVID-19 on the Project Covalence platform. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.011256},{"month":2,"riseRate":0.625,"avgChangeRate":0.014668},{"month":3,"riseRate":0.125,"avgChangeRate":-0.12582},{"month":4,"riseRate":0.571429,"avgChangeRate":0.029882},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.00606},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.054288},{"month":7,"riseRate":0.857143,"avgChangeRate":0.161352},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.106967},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.06312},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.062684},{"month":11,"riseRate":0.571429,"avgChangeRate":-0.055288},{"month":12,"riseRate":0.571429,"avgChangeRate":0.089966}],"exchange":"NASDAQ","name":"Adicet Bio, Inc.","nameEN":"Adicet Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adicet Bio, Inc.(ACET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adicet Bio, Inc.(ACET) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adicet Bio, Inc.,ACET,Adicet Bio, Inc.股票,Adicet Bio, Inc.股票老虎,Adicet Bio, Inc.股票老虎国际,Adicet Bio, Inc.行情,Adicet Bio, Inc.股票行情,Adicet Bio, Inc.股价,Adicet Bio, Inc.股市,Adicet Bio, Inc.股票价格,Adicet Bio, Inc.股票交易,Adicet Bio, Inc.股票购买,Adicet Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adicet Bio, Inc.(ACET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adicet Bio, Inc.(ACET) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction